Clinical Trial Update: HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial [Phase 3]

View source ↗

Summary

A Phase 3 randomized non-inferiority trial comparing HAIC with Oxaliplatin plus 2400 mg/m² 5-FU versus HAIC with Oxaliplatin plus 1200 mg/m² 5-FU in unresectabl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HAIC with Oxaliplatin + 5-FU

Snippet

Sponsor: Sun Yat-sen University | Conditions: HepatoCellular Carcinoma | Phase 3 | Status: UNKNOWN